Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy
Not yet recruiting
- Conditions
- Peripheral Diabetic NeuropathyPainful Diabetic Neuropathy
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Averitas Pharma, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06495424
- Locations
- 🇺🇸
Celéri Health, Inc, Conshohocken, Pennsylvania, United States
🇺🇸Clinical Research Strategies, LLC, Wexford, Pennsylvania, United States
Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery
Phase 3
Active, not recruiting
- Conditions
- Post Surgical Neuropathic Pain
- Interventions
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Averitas Pharma, Inc.
- Target Recruit Count
- 409
- Registration Number
- NCT04967664
- Locations
- 🇪🇸
Clinica Gaias, Santiago de Compostela, Spain
🇪🇸Hospital Clinico Universitario de Valencia, Valencia, Spain
🇵🇱Linden Centrum Medyczne, Krakow, Poland
© Copyright 2025. All Rights Reserved by MedPath